The Release And Activation Of Gelatinases In Epithelial Ovarian Tumor

The first part: The Clinical Significance of Tissue Inhibitors of Matrix Metalloproteinase Expression in Patients with Epithelial Ovarian TumorObjective: To investigate the relationship between the expression of gelatinases and its tissue inhibitors and clinical characterization in patients with epithelial ovarian tumor.Methods: Semi quantitative reversetranscription-polymerase chain reaction (RT-PCR) was used to examine the expression of gelatinases and its tissue inhibitors in 60 epithelial ovarian cancer and 30 ovarian benign tumor.Results: The expression of TIMP-2 was not significantly lower in malignant tissues than that in benign tumor (p> 0.05), and it was significantly higher in progressive patients with epithelial ovarian tumor. The expression of TIMP-1 was significantly higher in malignant tissues than that in benign tumor (p< 0.01), and higher in stage UK IV ovarian cancer (p<0.01) and progressive patients (p<0.01). The ratio of MMP-9/TIMP-1 was not significantly higher in malignant tissues than that in benign tumor (p>0.05). The ratio of MMP-2/TIMP-2 was significantly higher in malignanttissues than that in benign tumor (p<0.01), and higher in stage UK IV ovarian cancer (p<0.05).Conclusions: Gelatinase and its tissue inhibitors were generally expressed in epithelial tumor. There was a significantly correlation between the ratio of MMP-2/TIMP-2 and the invasion and metastasis of epithelial ovarian cancer. The ratio of MMP-2/TIMP-2 is a prognostic indicator in patients with epithelial ovarian cancer.